Importer of Controlled Substances Application: Scientific Botanical Pharmaceutical, Inc., 29742-29743 [2020-10625]
Download as PDF
<![CDATA[
29742
Federal Register / Vol. 85, No. 96 / Monday, May 18, 2020 / Notices
Controlled substance
Drug code
Tetrahydrocannabinols .....................................................................................................................................................
Codeine-N-oxide ...............................................................................................................................................................
Dihydromorphine ..............................................................................................................................................................
Difenoxin ...........................................................................................................................................................................
Morphine-N-oxide .............................................................................................................................................................
Normorphine .....................................................................................................................................................................
Norlevorphanol .................................................................................................................................................................
Acetyl Fentanyl (N-(1-phenethylpiperidin-4-yl)-N-phenylacetamide) ................................................................................
Butyryl Fentanyl ................................................................................................................................................................
Fentanyl related-substances as defined in 21 CFR 1308.11(h) ......................................................................................
Amphetamine ...................................................................................................................................................................
Methamphetamine ............................................................................................................................................................
Lisdexamfetamine ............................................................................................................................................................
Methylphenidate ...............................................................................................................................................................
Nabilone ...........................................................................................................................................................................
4-Anilino-N-phenethyl-4-piperidine (ANPP) ......................................................................................................................
Codeine ............................................................................................................................................................................
Dihydrocodeine .................................................................................................................................................................
Oxycodone .......................................................................................................................................................................
Hydromorphone ................................................................................................................................................................
Diphenoxylate ...................................................................................................................................................................
Ecgonine ...........................................................................................................................................................................
Hydrocodone ....................................................................................................................................................................
Levorphanol ......................................................................................................................................................................
Meperidine ........................................................................................................................................................................
Methadone ........................................................................................................................................................................
Methadone intermediate ...................................................................................................................................................
Dextropropoxyphene, bulk (non-dosage forms) ...............................................................................................................
Morphine ...........................................................................................................................................................................
Oripavine ..........................................................................................................................................................................
Thebaine ...........................................................................................................................................................................
Opium tincture ..................................................................................................................................................................
Opium, powdered .............................................................................................................................................................
Oxymorphone ...................................................................................................................................................................
Noroxymorphone ..............................................................................................................................................................
Alfentanil ...........................................................................................................................................................................
Remifentanil ......................................................................................................................................................................
Sufentanil ..........................................................................................................................................................................
Tapentadol ........................................................................................................................................................................
Fentanyl ............................................................................................................................................................................
The company plans to manufacture
bulk active pharmaceutical ingredients
(APIs) for distribution to its customers.
In reference to drug code 7370
(Tetrahydrocannabinols), the company
plans to bulk manufacture this drug as
synthetic. No other activities for this
drug code is authorized for this
registration.
William T. McDermott,
Assistant Administrator.
Drug Enforcement Administration
[Docket No. DEA–646]
Importer of Controlled Substances
Application: Scientific Botanical
Pharmaceutical, Inc.
ACTION:
Notice of application.
Registered bulk manufacturers of
the affected basic class(es), and
applicants therefore, may file written
comments on or objections to the
issuance of the proposed registration on
or before June 17, 2020. Such persons
may also file a written request for a
hearing on the application on or before
June 17, 2020
ADDRESSES: Written comments should
be sent to: Drug Enforcement
Administration, Attention: DEA Federal
Register Representative/DPW, 8701
DATES:
[FR Doc. 2020–10601 Filed 5–15–20; 8:45 am]
BILLING CODE 4410–09–P
jbell on DSKJLSW7X2PROD with NOTICES
DEPARTMENT OF JUSTICE
Jkt 250001
PO 00000
Frm 00064
Fmt 4703
In
accordance with 21 CFR 1301.34(a), this
is notice that on January 27, 2017,
Scientific Botanical Pharmaceutical,
Inc., 1225 West Deer Valley Road
Phoenix, Arizona 85027, applied to be
registered as an importer of the
following basic class(es) of controlled
substances:
Drug Code
Sfmt 4703
I
I
I
I
I
I
I
I
I
I
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
SUPPLEMENTARY INFORMATION:
Marihuana ................................................................................................................................................................
18:03 May 15, 2020
7370
9053
9145
9168
9307
9313
9634
9821
9822
9850
1100
1105
1205
1724
7379
8333
9050
9120
9143
9150
9170
9180
9193
9220
9230
9250
9254
9273
9300
9330
9333
9630
9639
9652
9668
9737
9739
9740
9780
9801
Morrissette Drive, Springfield, Virginia
22152. All requests for a hearing must
be sent to: Drug Enforcement
Administration, Attn: Administrator,
8701 Morrissette Drive, Springfield,
Virginia 22152. All requests for a
hearing should also be sent to: (1) Drug
Enforcement Administration, Attn:
Hearing Clerk/OALJ, 8701 Morrissette
Drive, Springfield, Virginia 22152; and
(2) Drug Enforcement Administration,
Attn: DEA Federal Register
Representative/DPW, 8701 Morrissette
Drive, Springfield, Virginia 22152.
Controlled substance
VerDate Sep<11>2014
Schedule
E:\FR\FM\18MYN1.SGM
18MYN1
7360
Schedule
I
29743
Federal Register / Vol. 85, No. 96 / Monday, May 18, 2020 / Notices
Controlled substance
Drug Code
Tetrahydrocannabinols ............................................................................................................................................
The company plans to import the
listed controlled substances as seeds,
cuttings, or other plant tissue material
in order to conduct research on genetic
development and manufacturing
processes. This notice does not
constitute an evaluation or
determination of the merits of the
company’s application.
William T. McDermott,
Assistant Administrator.
[FR Doc. 2020–10625 Filed 5–15–20; 8:45 am]
BILLING CODE 4410–09–P
DEPARTMENT OF JUSTICE
[OMB Number 1117–0006]
Agency Information Collection
Activities; Proposed eCollection,
eComments Requested; Revision of a
Previously Approved Collection; The
National Forensic Laboratory
Information System Collection of
Analysis Data
Drug Enforcement
Administration, Department of Justice.
ACTION: 60-Day Notice.
AGENCY:
The Department of Justice
(DOJ), Drug Enforcement
Administration (DEA), will be
submitting the following information
collection request to the Office of
Management and Budget for review and
approval in accordance with the
Paperwork Reduction Act of 1995.
DATES: Comments are encouraged and
will be accepted for 60 days until July
17, 2020.
FOR FURTHER INFORMATION CONTACT: If
you have comments, especially on the
estimated public burden or associated
response time, suggestions, or need a
copy of the proposed information
collection instrument with instructions
or additional information, please
contact Scott A. Brinks, Diversion
Control Division, Drug Enforcement
Administration; Mailing Address: 8701
Morrissette Drive, Springfield, Virginia
22152; Telephone: (571) 362–3261.
SUPPLEMENTARY INFORMATION: Written
comments and suggestions from the
public and affected agencies concerning
the proposed collection of information
are encouraged. Your comments should
address one or more of the following
four points:
—Evaluate whether the proposed
collection of information is necessary
jbell on DSKJLSW7X2PROD with NOTICES
SUMMARY:
VerDate Sep<11>2014
18:03 May 15, 2020
Jkt 250001
for the proper performance of the
functions of the agency, including
whether the information will have
practical utility;
—Evaluate the accuracy of the agency’s
estimate of the burden of the
proposed collection of information,
including the validity of the
methodology and assumptions used;
—Evaluate whether and if so how the
quality, utility, and clarity of the
information proposed to be collected
can be enhanced; and
—Minimize the burden of the collection
of information on those who are to
respond, including through the use of
appropriate automated, electronic,
mechanical, or other forms of
information technology, e.g.,
permitting electronic submission of
responses.
Overview of This Information
Collection
1. Type of Information Collection:
Revision of a currently approved
collection.
2. Title of the Form/Collection: The
National Forensic Laboratory
Information System Collection of
Analysis Data.
3. The agency form number, if any,
and the applicable component of the
Department sponsoring the collection:
There are no form numbers for the
collection. The applicable component
within the Department of Justice is the
Drug Enforcement Administration,
Diversion Control Division.
4. Affected public who will be asked
or required to respond, as well as a brief
abstract:
Affected public (Primary): Forensic
Science Laboratory Management.
Affected public (Other): None.
Abstract: This collection provides the
Drug Enforcement Administration
(DEA) with a national database on
analyzed drug evidence from nonfederal laboratories. Information from
this database is combined with the other
existing databases to develop more
accurate, up-to-date information on
abused drugs. This database represents
a voluntary, cooperative effort on the
part of participating laboratories to
provide a centralized source of analyzed
drug data.
5. An estimate of the total number of
respondents and the amount of time
estimated for an average respondent to
respond: The DEA estimates that 2,640
persons annually for this collection at
PO 00000
Frm 00065
Fmt 4703
Sfmt 4703
Schedule
7370
I
2.2 hour per respondent, for an annual
burden of 5,812 hours.
6. An estimate of the total public
burden (in hours) associated with the
proposed collection: The DEA estimates
this collection takes 5,812 annual
burden hours.
If additional information is required,
please contact: Melody Braswell,
Department Clearance Officer, United
States Department of Justice, Justice
Management Division, Policy and
Planning Staff, Two Constitution
Square, 145 N Street NE, Suite 3E.405B,
Washington, DC 20530.
Dated: May 12, 2020.
Melody Braswell,
Department Clearance Officer for PRA, U.S.
Department of Justice.
[FR Doc. 2020–10545 Filed 5–15–20; 8:45 am]
BILLING CODE 4410–09–P
DEPARTMENT OF JUSTICE
[OMB 1121–NEW]
Agency Information Collection
Activities; Proposed Collection
Comments Requested; New Data
Collection: Office for Victims of Crime
(OVC) Tribal Financial Management
Center (TFMC) Needs Assessment and
Evaluation OMB Package
Office for Victims of Crime,
Department of Justice.
ACTION: 60-day notice.
AGENCY:
The Department of Justice,
Office of Justice Programs, Office for
Victims of Crime will submit the
following information collection request
to the Office of Management and Budget
(OMB) for review and approval in
accordance with the Paperwork
Reduction Act of 1995. The proposed
information collection is published to
obtain comments from the public and
affected agencies.
DATES: The purpose of this notice is to
allow for an additional 60 days for
public comment until July 17, 2020.
FOR FURTHER INFORMATION CONTACT: If
you have additional comments
especially on the estimated public
burden or associated response time,
suggestions, or need a copy of the
proposed information collection
instrument with instructions or
additional information, please contact
please contact James Simonson,
Associate Director, (202) 353–9313,
Office for Victims of Crime, Office of
SUMMARY:
E:\FR\FM\18MYN1.SGM
18MYN1
]]>Agencies
[Federal Register Volume 85, Number 96 (Monday, May 18, 2020)]
[Notices]
[Pages 29742-29743]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2020-10625]
-----------------------------------------------------------------------
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
[Docket No. DEA-646]
Importer of Controlled Substances Application: Scientific
Botanical Pharmaceutical, Inc.
ACTION: Notice of application.
-----------------------------------------------------------------------
DATES: Registered bulk manufacturers of the affected basic class(es),
and applicants therefore, may file written comments on or objections to
the issuance of the proposed registration on or before June 17, 2020.
Such persons may also file a written request for a hearing on the
application on or before June 17, 2020
ADDRESSES: Written comments should be sent to: Drug Enforcement
Administration, Attention: DEA Federal Register Representative/DPW,
8701 Morrissette Drive, Springfield, Virginia 22152. All requests for a
hearing must be sent to: Drug Enforcement Administration, Attn:
Administrator, 8701 Morrissette Drive, Springfield, Virginia 22152. All
requests for a hearing should also be sent to: (1) Drug Enforcement
Administration, Attn: Hearing Clerk/OALJ, 8701 Morrissette Drive,
Springfield, Virginia 22152; and (2) Drug Enforcement Administration,
Attn: DEA Federal Register Representative/DPW, 8701 Morrissette Drive,
Springfield, Virginia 22152.
SUPPLEMENTARY INFORMATION: In accordance with 21 CFR 1301.34(a), this
is notice that on January 27, 2017, Scientific Botanical
Pharmaceutical, Inc., 1225 West Deer Valley Road Phoenix, Arizona
85027, applied to be registered as an importer of the following basic
class(es) of controlled substances:
------------------------------------------------------------------------
Controlled substance Drug Code Schedule
------------------------------------------------------------------------
Marihuana............................... 7360 I
[[Page 29743]]
Tetrahydrocannabinols................... 7370 I
------------------------------------------------------------------------
The company plans to import the listed controlled substances as
seeds, cuttings, or other plant tissue material in order to conduct
research on genetic development and manufacturing processes. This
notice does not constitute an evaluation or determination of the merits
of the company's application.
William T. McDermott,
Assistant Administrator.
[FR Doc. 2020-10625 Filed 5-15-20; 8:45 am]
BILLING CODE 4410-09-P
